Altimmune, Inc. (ALT)

Market Cap	628.84M
Revenue (ttm)	410,000
Net Income (ttm)	-92.77M
Shares Out	70.90M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,992,223
Open	8.04
Previous Close	7.82
Day's Range	8.02 - 8.97
52-Week Range	2.09 - 14.84
Beta	0.20
Analysts	Buy
Price Target	17.25 (+94.48%)
Earnings Date	May 9, 2024

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Vipin K. Garg Ph.D.
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT

Analyst Forecast

According to 5 analysts, the average rating for ALT stock is "Buy." The 12-month stock price forecast is $17.25, which is an increase of 94.48% from the latest price.

Price Target

$17.25

(94.48% upside)

Analyst Consensus: Buy